Objective To quantify naloxone and metabolite concentrations in newborns prenatally exposed to sublingual buprenorphine/naloxone and to correlate neonatal and maternal metabolite concentrations. Methods This is a prospective observational cohort study. Eleven pregnant women treated for opioid use disorder with sublingual buprenorphine/naloxone were enrolled. Maternal and newborn blood was colle...

Background: Buprenorphine dependence is a new issue and to our knowledge no scientific papers have been published on treatment of buprenorphine dependency. The goal of this research was to characterize intravenous buprenorphine-dependent individuals with respect to socio-demographic and other background features, and to investigate the effect of methadone in the maintenance treatment of intrave...

CONTEXT Bitter taste, as well as dissolve time, presents a significant challenge for the acceptability of formulations for oral transmucosal drug delivery. OBJECTIVE To characterize a novel sublingual tablet formulation of buprenorphine/naloxone with regards to pharmacokinetics, dissolve time and formulation acceptability. METHODS Dry mixing techniques were employed to produce a small and f...

Buprenorphine and buprenorphine-naloxone fixed combinations are effective for managing patients with opioid dependence, but constipation is one of the most common side effects. Evidence indicates that the rate of constipation is lower when patients are switched from sublingual buprenorphine-naloxone tablets or films to a bilayered bioerodible mucoadhesive buccal film formulation, and while the ...

Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of Iranian male opioid-dependent patients. Methods:A double-blind trial was carried out on a gro...

This study examines trends in the reported abuse of two sublingual buprenorphine products, Subutex and Suboxone, in the United States. Quarterly counts of abuse cases were obtained from 18 regional poison control centers (PCCS) for 2003-2005. Seventy-seven abuse cases were reported, of which 7.8 percent involved Subutex and 92.2 percent involved Suboxone. The average quarterly ratio of abuse ca...

RATIONALE Acute doses of buprenorphine can precipitate withdrawal in opioid dependent persons. The likelihood of this withdrawal increases as a function of the level of physical dependence. OBJECTIVES To test the acute effects of sublingual buprenorphine/naloxone tablets in volunteers with a higher level of physical dependence. The goal was to identify a dose that would precipitate withdrawal...

In addition to buprenorphine monotherapy tablets, film and tablets combining 4 parts buprenorphine and 1 part naloxone (a mu opioid antagonist) are also being used in maintenance treatment for opioid dependence (Chiang and Hawks, 2003). (The original manufacturer of the combination tablets stopped supplying them but generic versions and new brand, Zubsolv®*, are now available.) In fact, the bup...